Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia Sufferers

About this update from Silo Wellness Inc

[{"type":"text","content":"Psychedelics Company Silo Pharma Working On Time-Release And Dosage Ketamine Implant And Topical, Hoping To Deliver Steady Pain Relief For Four Million Fibromyalgia SufferersENGLEWOOD CLIFFS, NJ / ACCESSWIRE / June 23, 2023 / This month, Silo Pharma (NASDAQ:SILO) announced a new research and development agreement to create a time-release ketamine implant to treat fibromyalgia and other chronic pain conditions. The development-stage biopharma company has a portfolio of therapies in its pipeline that merge traditional therapeutics with the latest psychedelic research in its pipeline. Silo is aiming to leverage its existing partnerships with academic research institutions to help move this novel treatment for chronic pain sufferers through the Food and Drug Administration's approval process as efficiently as possible. The fibromyalgia market grew to $3.1 billion last year and is projected to keep growing at a compound annual growth rate of 4% over the next decade. Meanwhile, the larger chronic pain market is forecast to exceed $140 billion by 2030, with many chronic pain sufferers in desperate need of a treatment that delivers powerful pain relief without the serious side effects or risk of addiction that come with opioids.Time-Release Implants Put Ketamine's Pain-Relieving Potential In A More Practical Delivery FormatFor the estimated four million Americans with fibromyalgia, the chronic condition causes episodes of widespread pain throughout the body that have no specific cause. While the causes aren't yet clear, researchers believe the pain is rooted in the central nervous system, where disordered pain receptors become over-excited or dysregulated.Ketamine blocks the activity of the N-methyl-D-aspartate receptor (NMDAR), which is thought to play a role in amplifying pain signals sent to the brain from pain sensors around the body. In a systematic review of studies on intravenous ketamine infusions for patients with fibromyalgia, researchers found consistent evidence that the drug could relieve pain. But all studies faced a key challenge: the pain relief was short-term, wearing off a few hours after the infusion.For consistent pain management, patients would need frequent ketamine infusions for the duration of a flare-up, which can last anywhere from a few days to a few weeks. That's why Silo is working on a time-release implant....

More updates from Silo Wellness Inc